Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | PARP1 | P09874 | 2/20 | 0.53 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16462030 | 0.95 | ALDH1A1 (0.51) | ALDH1A1KDM4EPARP1PARP2TSHR | |
| SCHEMBL1385121 | 0.92 | PARP1 (0.54) | ALDH1A1KDM4EPARP1PARP2TSHR | |
| SCHEMBL18108811 | 0.87 | PARP1 (0.53) | ALDH1A1KDM4EPARP1PARP2TSHR | |
| SCHEMBL7527733 | 0.87 | PARP1 (0.53) | ALDH1A1KDM4EPARP1PARP2KMT2A | |
| SCHEMBL6043506 | 0.87 | ALDH1A1 (0.55) | ALDH1A1TSHRKMT2AMAPTLMNA | |
| SCHEMBL1381548 | 0.86 | HRH3 (0.58) | ALDH1A1PARP1PARP2KMT2ASIGMAR1 | |
| SCHEMBL2154542 | 0.85 | POLB (0.45) | ALDH1A1KDM4EPARP1PARP2TSHR | |
| SCHEMBL4502911 | 0.85 | HRH3 (0.57) | ALDH1A1PARP1PARP2KMT2AMAPT | |
| SCHEMBL2228234 | 0.85 | KDM4E (0.58) | ALDH1A1KDM4EPARP1PARP2KMT2A | |
| Hydrochloric Acid SCHEMBL8521067 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRKMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4274825-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2023-11-15 | — | — | EP | claimed |
| WO-2022150381-A1 | SELECTIVE INHIBITORS OF ROCK1 AND ROCK2 PROTEIN KINASES AND USES THEREOF | Genosco Inc. (US) | 2022-07-14 | — | — | WO | claimed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | claimed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | claimed |
| EP-2885284-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | Respivert Limited (GB) | 2015-06-24 | — | — | EP | claimed |
| WO-2014027209-A1 | PYRAZOLYL-UREAS AS KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2014-02-20 | — | — | WO | claimed |
| JP-4695588-B2 | — | — | 2011-06-08 | — | — | JP | claimed |
| JP-2006519232-A | — | — | 2006-08-24 | — | — | JP | claimed |
| EP-1603570-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | Sugen, Inc. (US) | 2005-12-14 | — | — | EP | claimed |
| WO-2004076412-A2 | AMINOHETEROARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | SUGEN, INC. (US) | 2004-09-10 | — | — | WO | claimed |
| EP-1112251-B1 | AZETIDINE DERIVATIVES, PREPARATION AND MEDICINES CONTAINING THEM | AVENTIS PHARMA SA (FR) | 2003-05-07 | — | — | EP | claimed |
| JP-2002532415-A | — | — | 2002-10-02 | — | — | JP | claimed |
| EP-1143957-A3 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2002-02-27 | — | — | EP | claimed |
| EP-1143957-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| EP-1140062-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2001-10-10 | — | — | EP | claimed |
| WO-2000040235-A2 | TREATMENT OF ASTHMA WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-07-13 | — | — | WO | claimed |
| WO-2000035436-A2 | TREATMENT OF ARTHRITIS WITH MEK INHIBITORS | WARNER-LAMBERT COMPANY (US) | 2000-06-22 | — | — | WO | claimed |
| WO-1998037881-A1 | METHOD OF TREATING OR PREVENTING SEPTIC SHOCK BY ADMINISTERING A MEK INHIBITOR | WARNER LAMBERT COMPANY (US) | 1998-09-03 | — | — | WO | claimed |
| EP-4735113-A1 | PYRAZOLE DERIVATIVES AS PD-1/PD-L1 INTERACTION INHIBITORS | Institut National de la Santé et de la Recherche Médicale (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-6310060-B1 | FOR USE AS ANTIPROLIFERATIVE AGENT FOR USE AGAINST CANCER, PSORIASIS, RESTENOSIS, AUTOIMMUNE DISEASE, OR ATHEROSCLEROSIS | WARNER-LAMBERT COMPANY | 2001-10-30 | — | — | US | disclosed |